A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

  • End date
    Jun 9, 2025
  • participants needed
  • sponsor
    Protagonist Therapeutics, Inc.
Updated on 9 August 2022
jak2 v617f


The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.


Phase 3 study in approximately 250 subjects previously diagnosed with polycythemia vera (PV) who require phlebotomy on a routine basis. There is a 32-week period during which rusfertide or placebo will be added-on to each subject's ongoing therapy for polycythemia vera which may include phlebotomy only or phlebotomy plus stable doses of either of hydroxyurea, interferon and/or ruxolitinib. All subjects who successfully complete the double blind 32-week portion of the study will receive rusfertide for 124 weeks.

Condition Polycythemia Vera
Treatment Placebo, Rusfertide
Clinical Study IdentifierNCT05210790
SponsorProtagonist Therapeutics, Inc.
Last Modified on9 August 2022


Yes No Not Sure

Inclusion Criteria

All subjects must meet ALL of the following inclusion
criteria to
be enrolled. There are additional inclusion criteria
Male and female subjects aged 18 (or the country specific minimum age of consent >18) years or older
Meet revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera and have either JAK2 V617F mutation or JAK2 exon 12 mutation
At least 3 phlebotomies due to inadequate hematocrit control in 6 months before randomization or at least 5 phlebotomies due to inadequate hematocrit control in 1 year before randomization
CBC values immediately prior to randomization
Hematocrit <45%
WBC 4000/μL to 20,000/μL (inclusive), and
Platelets 100,000/μL to 1,000,000/μL (inclusive)
Subjects receiving cytoreductive therapy at randomization must be on a stable PV
therapy regimen
Subjects treated with phlebotomy alone at randomization must have stopped cytoreductive therapy 2 to 6 months before screening

Exclusion Criteria

Subjects must meet NONE of the following exclusion criteria to be
enrolled. There are additional exclusion criteria
Clinically meaningful laboratory abnormalities at Screening
Subjects who require phlebotomy at hematocrit levels lower than 45%
Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein
thrombosis) within 2 months prior to randomization
Active or chronic bleeding within 2 months prior to randomization
History of invasive malignancies within the last 5 years, except localized cured
prostate cancer and cervical cancer
Subjects with non-invasive non-melanomatous (e.g., squamous cell or basal cell
carcinoma) skin cancer during screening unless adequately treated before
Received Busulfan, Pipobroman or 32Phosphorus within 7 months prior to screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note